Canada markets closed

Sanofi (SNY)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
52.67+0.53 (+1.02%)
At close: 04:00PM EDT
52.50 -0.17 (-0.32%)
After hours: 07:45PM EDT
Full screen
Trade prices are not sourced from all markets
Previous Close52.14
Open52.63
Bid51.95 x 800
Ask52.88 x 1200
Day's Range52.46 - 52.88
52 Week Range46.93 - 58.10
Volume1,773,589
Avg. Volume2,353,150
Market Cap131.534B
Beta (5Y Monthly)0.36
PE Ratio (TTM)18.81
EPS (TTM)2.80
Earnings DateN/A
Forward Dividend & Yield1.75 (3.35%)
Ex-Dividend DateMay 26, 2022
1y Target Est70.75
  • Reuters

    Sanofi caps out-of-pocket insulin cost at $35 for uninsured U.S. patients

    French drugmaker Sanofi said on Wednesday uninsured diabetes patients in the United States will pay no more than $35 for 30-day supply of insulin, in the wake of heightened public scrutiny over soaring prices of the life-saving drug. Sanofi said the new price, down from the prior out-of-pocket cost of $99, will be effective from July 1. U.S. lawmakers have pulled up healthcare companies over rising costs of insulin and the U.S. House of Representatives in March passed a bill capping monthly out-of-pocket insulin costs for those with health insurance at $35.

  • Zacks

    Sanofi (SNY) Wins Nod for Nexviadyme & Xenpozyme in Europe

    Sanofi's (SNY) Nexviadyme is approved for the treatment of both late-onset Pompe disease and infantile-onset Pompe disease. Xenpozyme is approved for non-Central Nervous System (CNS) manifestations of acid sphingomyelinase deficiency (ASMD) disease.

  • GlobeNewswire

    Press Release: Nexviadyme® (avalglucosidase alfa) approved by European Commission as a potential new standard of care for the treatment of Pompe Disease

    Nexviadyme® (avalglucosidase alfa) approved by European Commission as a potential new standard of care for the treatment of Pompe Disease Approved for the treatment of the full spectrum of both late-onset Pompe disease and infantile-onset Pompe diseaseFirst new treatment option approved for the Pompe community in Europe in more than 15 years Paris, June 28, 2022 – The European Commission has granted marketing authorization for Nexviadyme® (avalglucosidase alfa), an enzyme replacement therapy (ER